MacroGenics (MGNX) Projected to Post Quarterly Earnings on Thursday

MacroGenics (NASDAQ:MGNX) is expected to be announcing its earnings results after the market closes on Thursday, March 20th. Analysts expect the company to announce earnings of ($0.23) per share and revenue of $34.17 million for the quarter. Investors that are interested in participating in the company’s conference call can do so using this link.

MacroGenics Trading Down 1.8 %

MGNX opened at $2.18 on Tuesday. MacroGenics has a twelve month low of $2.14 and a twelve month high of $19.54. The stock has a market cap of $136.82 million, a PE ratio of -1.38 and a beta of 2.12. The business’s 50 day moving average is $2.75 and its 200-day moving average is $3.26.

MacroGenics Company Profile

MacroGenics, Inc, a biopharmaceutical company, develops, manufactures, and commercializes antibody-based therapeutics to treat cancer in the United States. Its approved product is MARGENZA (margetuximab-cmkb), a human epidermal growth factor receptor 2 (HER2) receptor antagonist indicated, in combination with chemotherapy, for the treatment of adult patients with metastatic HER2-positive breast cancer who have received two or more prior anti-HER2 regimens.